Learn more about the team working behind-the-scenes at the Cellnovo office to simplify
the lives of people with diabetes
Cellnovo Group SA is an independent medical technology company specialising in diabetes. We have developed and market the first mobile, connected, all-in-one diabetes management system that helps make life easier for people with diabetes.
Compact, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time.
Cellnovo announces the launch of its Gen 3 System, which includes a locked-down consumer-grade Android phone linked via Bluetooth Low Energy to its micro-pump for insulin delivery.
Cellnovo Group announces its sales and results for the first half ended June 30, 2018.
Cellnovo Group announces the commercialisation of insulin cartridges produced by Flex following the successful start of large-scale manufacturing in Althofen, Austria.
Cellnovo Group informs its shareholders and the financial community that the combined general meeting of Cellnovo shareholders held on May 24 was able to validly deliberate, the quorum having been largely reached.
Le Groupe Cellnovo informe ses actionnaires et l’ensemble de la communauté financière que les documents relatifs à l’Assemblée Générale Mixte qui se tiendra le jeudi 24 mai 2018 à 14h au Centre de Conférences Capital 8, 32 rue de Monceau, 75008 Paris, sont disponibles sur simple demande auprès de la société, ou peuvent être consultés sur le site Internet http://www.cellnovo.fr, rubrique Investisseurs / Assemblée Générale.
Le Groupe Cellnovo annonce aujourd’hui avoir mis à la disposition du public et déposé auprès de l'Autorité des marchés financiers son rapport financier annuel au 31 décembre 2017.
Cellnovo Group announces its full year results for the financial year ended on December 31, 2017, and its first-quarter 2018 sales.
Cellnovo Group announces the publication of the results of a retrospective study highlighting the efficacy of Cellnovo’s Diabetes Management System.
Cellnovo reports its revenue from sales, and its cash position at December 31, 2017.
Cellnovo publishes its financial calendar for the year 2018.
Cellnovo provides an update on manufacturing of insulin cartridges with its manufacturing partner, Flex.
2017 FY sales
Wednesday, January 17, 2018
2017 FY results and 2018 Q1 sales
Thursday, April 12, 2018
Thursday, May 24, 2018
2018 H1 sales and results
Thursday, July 26, 2018
2018 Q3 sales
Thursday, October 11, 2018